TRDA Overview

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Wall Street analysts forecast TRDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRDA is16.50 USD with a low forecast of 13.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Entrada Therapeutics Inc revenue for the last quarter amounts to 1.30M USD, decreased -96.53

Entrada Therapeutics Inc. EPS for the last quarter amounts to -0.94 USD, decreased -3233.33

Entrada Therapeutics Inc (TRDA) has 152 emplpoyees as of March 25 2026.

Today TRDA has the market capitalization of 439.12M USD.